Restart Life Sciences Corp.
NMLSF
$0.032
-$0.0265-45.30%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -20.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -20.80K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -20.80K |
| SG&A Expenses | 203.50K | 87.20K | 61.10K | 100.90K | 140.90K |
| Depreciation & Amortization | 400.00 | 400.00 | 400.00 | 400.00 | 500.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 203.90K | 87.70K | 61.50K | 101.70K | 141.90K |
| Operating Income | -203.90K | -87.70K | -61.50K | -101.70K | -162.70K |
| Income Before Tax | 100.00 | 336.90K | -66.20K | -107.10K | -154.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 100.00 | 336.90K | -66.20K | -107.10K | -154.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 100.00 | 336.90K | -66.20K | -107.10K | -154.00K |
| EBIT | -203.90K | -87.70K | -61.50K | -101.70K | -162.70K |
| EBITDA | -203.50K | -87.20K | -61.10K | -101.30K | -162.10K |
| EPS Basic | 0.00 | 0.02 | 0.00 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -0.01 | 0.01 | 0.00 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 16.67M | 14.83M | 14.81M | 14.81M | 14.72M |
| Average Diluted Shares Outstanding | 18.50M | 15.32M | 14.81M | 14.81M | 14.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |